SHANK1 Antibody

What is SHANK1 and why is it important in neuroscience research?

SHANK1 (SH3 and multiple ankyrin repeat domains 1) functions as an adapter protein in the postsynaptic density (PSD) of excitatory synapses, where it interconnects receptors of the postsynaptic membrane—including NMDA-type and metabotropic glutamate receptors—via complexes with GKAP/PSD-95 and Homer, respectively, and links to the actin-based cytoskeleton . This structural role is critical for the organization and function of dendritic spines and synaptic junctions .

SHANK1 is primarily expressed in the brain, with particularly high levels in the amygdala, hippocampus, substantia nigra, and thalamus . Recent research has revealed that SHANK1 is highly localized in Parvalbumin-expressing (PV+) fast-spiking inhibitory interneurons in hippocampus . The protein's importance extends beyond structural roles, as loss of SHANK1 in hippocampal CA1 PV+ neurons reduces excitatory synaptic inputs and inhibitory synaptic outputs to pyramidal neurons, leading to a shift in excitatory and inhibitory balance (E-I balance), which is a pathophysiological hallmark of autism spectrum disorder (ASD) .

What are the key molecular characteristics of SHANK1 protein?

The human SHANK1 protein has the following key characteristics:

SHANK1 is composed of several protein-protein interaction domains that enable it to function as a molecular scaffold . The protein's multiple domains allow it to crosslink various receptor complexes and connect them to the cytoskeleton, creating an organized network at synaptic junctions .

What applications are SHANK1 antibodies typically used for?

SHANK1 antibodies are employed across multiple experimental applications in neuroscience and related fields. The following table summarizes common applications with typical dilution ranges:

Researchers should note that optimal dilutions may vary depending on specific experimental conditions, tissue types, and the particular antibody used. Titration experiments are recommended when establishing a new protocol or when using a new antibody source .

How should I select the most appropriate SHANK1 antibody for my specific research application?

Selecting the appropriate SHANK1 antibody requires consideration of multiple factors to ensure experimental success:

• Target epitope consideration: Select antibodies targeting relevant epitopes based on your research question. For instance, if studying full-length SHANK1, choose antibodies recognizing conserved regions. Available epitopes include:

  • C-terminus (e.g., residues [SGPIYPGLFDIRSS])

  • Region near amino acids 450-700

  • Other specific domains depending on the antibody product

• Antibody type selection: Consider whether polyclonal or monoclonal antibodies better suit your needs:

  • Polyclonal antibodies (e.g., 55059-1-AP, NB300-167) offer high sensitivity by recognizing multiple epitopes but may show batch-to-batch variation

  • Monoclonal antibodies (e.g., ab94576, N22/21R) provide high specificity and reproducibility, making them valuable for quantitative applications

• Species reactivity: Verify that the antibody recognizes SHANK1 in your experimental species. Available antibodies show reactivity with:

  • Human SHANK1

  • Mouse SHANK1

  • Rat SHANK1

• Cross-reactivity assessment: Some antibodies specifically recognize only SHANK1, while others (e.g., 162 105) detect multiple SHANK family members (SHANK1/2/3) . Choose according to your research requirements.

• Validation evidence: Prioritize antibodies with extensive validation data including:

  • Published references

  • Knockout/knockdown controls

  • Multiple application validations

  • Positive control tissue/cell recommendations

Implementing a systematic selection process based on these criteria will significantly improve the likelihood of obtaining reliable and reproducible results in your SHANK1 research.

What are the optimal sample preparation methods for detecting SHANK1 in different neuronal preparations?

Effective sample preparation is critical for successful SHANK1 detection in various neuronal preparations:

For Western Blot Analysis:

• Tissue homogenization: For brain tissue samples, use ice-cold RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors to preserve post-translational modifications.

• Cell lysis optimization: For neuronal cultures or cell lines (such as HEK-293T or Neuro-2a), complete lysis is essential as SHANK1 is tightly associated with the cytoskeleton .

• Protein denaturation: Use reducing conditions and complete denaturation (95°C for 5 minutes) to ensure proper size migration, as SHANK1 is a large protein (observed at 159-225 kDa) .

For Immunohistochemistry/Immunofluorescence:

• Fixation methods: 4% paraformaldehyde fixation is commonly used for brain tissue sections and cultured neurons. For some applications, Bouin's fixation has been successfully employed .

• Antigen retrieval: Heat-mediated antigen retrieval may be necessary for paraffin-embedded sections to expose the SHANK1 epitope.

• Permeabilization: Use 0.1% PBS-Tween or 0.1-0.3% Triton X-100 for effective antibody penetration .

For Cellular Localization Studies:

• Z-stack imaging: For accurate localization in dendritic spines and synapses, capture Z-series projections of x-y images at 0.2-1 μm depth intervals .

• Co-staining recommendations: Combine SHANK1 antibody staining with markers for:

  • Presynaptic terminals (e.g., synaptophysin)

  • Postsynaptic scaffolds (e.g., PSD-95)

  • Cell-type specific markers (e.g., parvalbumin for PV+ interneurons)

Special Considerations:

• When studying PV+ interneurons, ensure co-labeling with appropriate markers to distinguish from pyramidal neurons

• For detection in non-neuronal tissues (e.g., lung cancer cells as in NSCLC research), optimization of lysis buffers may be required

• SHANK1-decorated neurons can be identified by immunoreactivity in both the cell body and dendritic segments

How can I troubleshoot common issues with SHANK1 antibody experiments?

When working with SHANK1 antibodies, researchers may encounter several challenges. The following troubleshooting guide addresses common issues:

Issue: Weak or absent signal in Western blot

• Potential causes and solutions:

  • Insufficient protein: Increase loading amount (30-50 μg recommended for brain tissue)

  • Inadequate transfer: Extend transfer time for high molecular weight SHANK1 (recommended 2+ hours at 30V or overnight at 15V)

  • Antibody dilution: Optimize antibody concentration; try lower dilutions (1:500 rather than 1:1000)

  • Detection method: Consider more sensitive detection systems (ECL Plus rather than standard ECL)

  • Antigen degradation: Ensure complete protease inhibition during sample preparation

Issue: High background in immunostaining

• Potential causes and solutions:

  • Excessive antibody: Increase dilution (try 1:500 instead of 1:50)

  • Insufficient blocking: Extend blocking time (2+ hours) or use alternative blocking agents (5% BSA or 10% normal serum)

  • Inadequate washing: Increase washing steps and duration (5× 10-minute washes)

  • Fixation issues: Optimize fixation protocol; overfixation can increase background

  • Autofluorescence: Include Sudan Black B treatment to reduce tissue autofluorescence

Issue: Multiple bands in Western blot

• Potential causes and solutions:

  • SHANK1 isoforms: Confirm band pattern against literature; multiple isoforms may be present

  • Protein degradation: Ensure complete protease inhibition and appropriate sample handling

  • Nonspecific binding: Increase blocking time and optimize antibody dilution

  • Cross-reactivity: Some antibodies detect multiple SHANK family members; verify antibody specificity

Issue: Inconsistent results between experiments

• Potential causes and solutions:

  • Antibody stability: Aliquot antibodies and store at recommended temperatures

  • Sample preparation variability: Standardize protocols for tissue/cell preparation

  • Antibody batch variation: Particularly relevant for polyclonal antibodies; maintain consistent lot numbers when possible

  • Cell/tissue heterogeneity: Ensure consistent sampling from specific brain regions

Advanced troubleshooting approaches:

• Validate antibody specificity using knockdown/knockout controls

• Perform peptide competition assays to confirm epitope specificity

• Try alternative fixation protocols for immunohistochemistry applications

• Consider epitope accessibility in your experimental system

How can SHANK1 antibodies be utilized to investigate excitatory-inhibitory balance in neuropsychiatric disorders?

Recent research has revealed SHANK1's critical role in regulating excitatory-inhibitory (E-I) balance, making SHANK1 antibodies valuable tools for investigating neuropsychiatric disorders:

Methodological Approach for E-I Balance Investigation:

• Dual-labeling immunofluorescence techniques:

  • Co-label with SHANK1 antibodies (1:10000 dilution, e.g., Abcam ab66315 or Synaptic Systems 162013) and cell-type specific markers to examine SHANK1 distribution in both excitatory and inhibitory neurons

  • Quantitative analysis of SHANK1 signals in dendritic segments of PV+ neurons compared to surrounding neuropil regions provides insight into differential expression patterns

• Electrophysiological correlation analysis:

  • Combine immunostaining with patch-clamp recordings to correlate SHANK1 expression levels with functional properties of synapses

  • Measure miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) in neurons with defined SHANK1 expression levels

• Molecular markers of E-I balance:

  • Use SHANK1 antibodies in conjunction with antibodies against:

    • Excitatory synapse markers (PSD-95, GluA1, GluN1)

    • Inhibitory synapse markers (gephyrin, GABA receptor subunits)

    • Presynaptic terminal markers (synaptophysin, vesicular transporters)

  • Quantitative analysis of co-localization and relative expression levels provides insights into synaptic composition

• Implementation in disease models:

  • Apply these techniques to animal models of autism spectrum disorder (ASD), schizophrenia, and other conditions with E-I balance disruptions

  • Compare SHANK1 distribution in PV+ interneurons between control and disease models

  • Hippocampal CA1 region is particularly relevant as SHANK1 mutant mice exhibit E-I balance shifts in this region

The significance of this approach is underscored by findings that SHANK1 is highly localized in PV+ fast-spiking inhibitory interneurons, and its absence reduces excitatory inputs to these cells and consequently diminishes inhibitory outputs to pyramidal neurons . This creates an E-I imbalance that may contribute to ASD-related behavioral phenotypes. Researchers can leverage SHANK1 antibodies to further investigate this mechanism across various neuropsychiatric conditions.

What approaches can be used to study SHANK1's potential role in non-neuronal tissues, particularly in cancer?

Recent evidence suggests SHANK1 may function beyond the nervous system, particularly in cancer, opening new research avenues:

Methodological Framework for Studying SHANK1 in Cancer:

• Expression profiling in cancer tissues:

  • Western blot analysis using SHANK1-specific antibodies (e.g., 55059-1-AP at 1:500-1:1000 dilution) to compare expression levels between:

    • Tumor tissues vs. adjacent normal tissues

    • Cancer cell lines vs. normal cell counterparts

    • Different cancer types and stages

  • Immunohistochemistry with optimized protocols for non-neural tissues to evaluate spatial distribution within tumors

• Functional analysis in cancer models:

  • Combine SHANK1 antibodies with markers of:

    • Cell proliferation (Ki-67, PCNA)

    • Invasion/migration (MMPs, EMT markers)

    • Apoptosis (cleaved caspase-3, PARP)

  • Correlate SHANK1 expression patterns with these functional parameters

• Protein interaction network investigations:

  • Immunoprecipitation (IP) using SHANK1 antibodies (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) to identify:

    • Novel interacting partners in cancer cells

    • Cancer-specific protein complexes

    • Post-translational modifications unique to cancer contexts

  • Specifically investigate interactions with known cancer-related proteins like MDM2 and Klotho (KL)

• Mechanistic studies of SHANK1 in cancer:

  • Focus on SHANK1's newly discovered role in protein degradation pathways:

    • Use SHANK1 antibodies to track complex formation with KL and MDM2

    • Investigate ubiquitination-dependent degradation of tumor suppressors

    • Analyze SHANK1-dependent changes in protein stability

This approach is supported by recent findings that SHANK1 is upregulated in non-small cell lung cancer (NSCLC) and contributes to cancer cell proliferation, migration, and invasion . Mechanistically, SHANK1 increases the protein degradation of the tumor suppressor Klotho through an ubiquitination-dependent pathway, forming a complex with KL and the E3 ubiquitin ligase MDM2 . These discoveries suggest SHANK1 antibodies can be valuable tools for investigating novel oncogenic mechanisms beyond their traditional applications in neuroscience.

How can multiplexed imaging with SHANK1 antibodies enhance our understanding of synaptic organization?

Advanced multiplexed imaging techniques using SHANK1 antibodies can provide unprecedented insights into synaptic architecture:

Cutting-Edge Multiplexed Imaging Approaches:

• Multi-epitope labeling strategies:

  • Combine multiple SHANK1 antibodies targeting different epitopes:

    • C-terminal epitopes (e.g., [SGPIYPGLFDIRSS])

    • Mid-region epitopes (e.g., residues 450-700)

    • N-terminal domains

  • This approach allows visualization of different SHANK1 domains within the postsynaptic density, revealing structural organization

• Array tomography with SHANK1 antibodies:

  • Ultrathin (70-200 nm) serial sections combined with immunofluorescence

  • Sequential antibody labeling and stripping rounds allow for:

    • High-resolution 3D reconstruction of synapses

    • Precise localization of SHANK1 relative to other synaptic proteins

    • Quantitative analysis of protein distribution at nanoscale resolution

• Super-resolution microscopy applications:

  • STORM/PALM techniques with SHANK1 antibodies achieve 10-20 nm resolution

  • STED microscopy with appropriate secondary antibodies for live-cell imaging

  • Recommended antibody dilutions may need optimization for these techniques (typically higher concentrations than conventional imaging)

• Multiparametric analysis of synaptic composition:

  • Combine SHANK1 antibodies with markers for:

    • Other scaffold proteins (PSD-95, Homer, GKAP)

    • Receptor subunits (AMPA, NMDA, mGluR)

    • Cytoskeletal elements (F-actin, cortactin)

    • Synaptic adhesion molecules (neurexins, neuroligins)

  • This provides comprehensive mapping of molecular interrelationships at synapses

• Quantitative image analysis protocols:

  • Measure size, intensity, and density of immunopositive signals using MetaMorph software or similar tools

  • Apply distance-based colocalization analyses rather than simple pixel overlap

  • Implement machine learning algorithms for pattern recognition in complex datasets

This methodology leverages recent findings about SHANK1's differential expression in specific neuron types (e.g., high localization in PV+ interneurons) and can reveal how SHANK1 distribution varies across brain regions and cell types . The approach allows researchers to investigate how SHANK1 contributes to synaptic diversity and specificity, potentially uncovering principles of synaptic organization relevant to both normal function and disease states.

How should researchers interpret SHANK1 antibody data when results from different detection methods appear contradictory?

Researchers frequently encounter seemingly contradictory results when using multiple methods to study SHANK1. The following framework helps reconcile and interpret such discrepancies:

Systematic Approach to Resolving Contradictory Results:

• Recognize method-specific limitations:

  • Western blot detects denatured protein and may miss conformational epitopes

  • Immunohistochemistry preserves spatial information but may have limited sensitivity

  • Immunoprecipitation captures protein complexes but may disrupt weak interactions

  • Flow cytometry provides quantitative data but loses spatial context

• Evaluate antibody characteristics across methods:

  • Epitope accessibility varies between applications:

    • Linear epitopes work better in Western blot after complete denaturation

    • Conformational epitopes may be preserved only in specific fixation conditions

  • Consider cross-reactivity with other SHANK family members:

    • Some antibodies (e.g., 162 105) recognize all SHANK proteins

    • Others are highly specific for SHANK1

• Analyze protein context and modifications:

  • SHANK1 exists in multiple isoforms (observed molecular weights 159-225 kDa)

  • Post-translational modifications affect antibody recognition

  • Protein interactions may mask epitopes in specific cellular compartments

  • Expression levels vary dramatically between brain regions and cell types

• Reconciliation strategies for contradictory data:

  • Implement controls specific to each detection method:

    • Recombinant protein standards for Western blot

    • Known positive tissues for immunohistochemistry

    • Knockout/knockdown samples as negative controls

  • Use multiple antibodies targeting different epitopes

  • Apply orthogonal detection methods to validate findings

• Case example: Resolving discrepancies in SHANK1 localization

  • Western blot may show SHANK1 expression throughout brain homogenates

  • Immunohistochemistry reveals cell-type specific distribution (high in PV+ neurons)

  • Both results are valid when considering the method-specific resolution and context

This systematic approach acknowledges that each method provides a different perspective on SHANK1 biology, and apparent contradictions often reflect complementary aspects of the protein's complex behavior in biological systems .

What are the implications of recent findings about SHANK1's role in both excitatory and inhibitory synaptic function?

Recent discoveries about SHANK1's dual role in excitatory and inhibitory synaptic function have profound implications for neuroscience research:

Implications for Basic Neuroscience:

• Revision of canonical SHANK1 function:

  • Traditional view: SHANK1 primarily organized excitatory postsynaptic densities

  • Current understanding: SHANK1 regulates both excitatory inputs to inhibitory neurons and inhibitory outputs to pyramidal cells

  • This dual role positions SHANK1 as a master regulator of network excitability

• Cell-type specific functions:

  • High localization in PV+ interneurons suggests specialized roles in inhibitory circuits

  • Different molecular partners may interact with SHANK1 in different neuronal populations

  • SHANK1 may organize distinct postsynaptic architectures depending on cell type

• Synaptic plasticity mechanisms:

  • SHANK1 likely contributes to both Hebbian and homeostatic plasticity

  • Its dual regulation of excitatory and inhibitory function may coordinate synaptic scaling

  • Regulation of E-I balance suggests involvement in metaplasticity mechanisms

Implications for Disease Understanding:

• Neurodevelopmental disorders:

  • E-I imbalance in SHANK1 mutant mice mirrors a core pathophysiological hallmark of ASD

  • SHANK1's dual synaptic role may explain the complex behavioral phenotypes in SHANK1-related disorders

  • Mutations might differentially affect excitatory versus inhibitory function

• Therapeutic target development:

  • Cell-type specific SHANK1 manipulation could restore E-I balance

  • Interventions might need to target specific SHANK1 interactions rather than total protein levels

  • Developmental timing considerations become critical given SHANK1's role in circuit formation

• Biomarker potential:

  • SHANK1 expression patterns might serve as indicators of altered E-I balance

  • Antibody-based imaging could potentially identify circuit-specific disruptions

  • Profiles of SHANK1 interactions might characterize specific disease states

Methodological Implications:

• Experimental design considerations:

  • Cell-type specific analysis is essential when studying SHANK1 function

  • Combined structural and functional assessments provide more complete understanding

  • Developmental timepoints must be carefully considered

• Antibody application strategies:

  • Multiplexed labeling to simultaneously assess SHANK1 in both neuron types

  • Quantitative approaches to measure relative distribution between cell populations

  • Live-cell imaging to track dynamic changes in SHANK1 distribution

These findings fundamentally change how we conceptualize SHANK1's role in neural circuits and provide new frameworks for investigating excitatory-inhibitory balance in both normal brain function and disease states .